Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction. Measures used to assess polyneuropathy in other diseases have been tested as endpoints in hATTR amyloidosis clinical trials (i.e. Neuropathy Impairment Score [NIS], NIS-lower limb, and NIS+7), yet the unique nature of the polyneuropathy in this disease has necessitated modifications to these scales. In particular, the heterogeneous impairment and the aggressive disease course have been key drivers in developing scales that better capture the disease burden and progression of polyneuropathy in hATTR amyloidosis.
A C C E P T E D M A N U S C R I P T
The extent of disability has been a longstanding measure of neuropathic burden in hATTR amyloidosis, typically captured by the Familial Amyloidotic Polyneuropathy (FAP) staging system and/or the polyneuropathy disability (PND) scoring system. FAP staging was developed in an endemic area of Portugal in 1980 [16] , and encompasses three stages: FAP stage 1 is defined by unassisted walking, in which patients typically experience mild bilateral neuropathy in the feet and legs [16, 17] ; stage 2 is defined by the patient requiring assistance walking with crutches or sticks, with neuropathy developing throughout the body [16, 17] ; and stage 3 is defined by the patient becoming wheelchair-bound or bedridden, with severe neuropathy [16, 17] . PND scoring involves a greater separation of disease stages: a score of I indicates sensory disturbance but with preserved walking capacity; II indicates unassisted walking but with difficulty; IIIa indicates one stick or crutch is required for walking;
IIIb indicates two sticks or crutches are required for walking; and IV indicates the patient is wheelchair-bound or bedridden [18] .
While assessing polyneuropathy in hATTR amyloidosis in this manner can provide a broad indicator of overall disease state, it can take up to 5 years for patients to transition from one FAP stage/PND score to another [17] . As such, these measures are insensitive to tracking disease progression over shorter time periods and are impractical for use as primary outcome measures in clinical trials. Hence, the Neuropathy Impairment Score (NIS), the NIS lower limb (NIS-LL; a subset of the NIS), and the NIS+7 (a variation of NIS that includes nerve conduction studies and quantitative sensory and autonomic endpoints) have all been utilized in studies of patients with hATTR amyloidosis [19, 20] . These tools were developed, and have been used successfully, across a range of neuropathies [21] [22] [23] ], yet their value for hATTR amyloidosis is limited due to the unique nature of this disease. For example, hATTR amyloidosis with polyneuropathy has a more rapid progression than diabetic polyneuropathy [5, 24] , and a wider range of impairment (especially sensory and autonomic) compared with chronic inflammatory demyelinating polyneuropathy [13] . To better capture the different features of polyneuropathy in patients with hATTR amyloidosis,
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and to afford more sensitive detection of disease progression (or even improvement with treatment), these scales have been modified to create the modified NIS+7 (mNIS+7) [25] [26] [27] .
As the primary endpoint in two recent phase III trials, this has become an important measure of polyneuropathy as part of this multisystem disease. This article will discuss the assessment of polyneuropathy in hATTR amyloidosis, the use of NIS and NIS-based scales, and reflect on how and why the different scales have evolved toward the mNIS+7 iteration.
NIS
NIS was designed to provide standard, quantitative, and overall scores of neurologic impairments for the purpose of ongoing evaluation of patients in clinical trials and epidemiologic studies [28] . In addition, it can be used to quantify impairment and progression of neuromuscular conditions at diagnosis and during treatment [28] . It is a composite score of clinical impairments (weakness, reflex loss, and sensory loss) using standard assessment of muscle weakness and groups of muscles, reflexes and sensory modalities at specific sites on both sides of the body (Table 1) , and was constructed to provide a balance between these impairments but with the greatest emphasis on weakness [21] . The total NIS is graded on a scale of 0-244, with a higher score indicating greater impairment [29]; a 2-point change is considered the least degree of change a physician could recognize [30] . NIS was developed from two historical approaches to grading neurologic impairment, one from the medical research council (MRC) and the other from the Mayo Clinic (Rochester, MN). The Mayo Clinic grading approach, which measures weakness and sensation loss using a linear scale of severity, was adopted over the MRC approach which was designed for assessment of very severe neurologic damage and only evaluates muscle weakness [28] .
To assess the reproducibility of NIS, 12 trained investigators (neurophysiologists and diabetologists) graded 24 masked patients on two occasions with or without varying severities of diabetic polyneuropathy. In this study, in which patients' neuropathic signs were assessed based on individual physicians' usual evaluations, intra-and inter-test variability
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A C C E P T E D M A N U S C R I P T was high [31] . However, in a repeat study, in which the physicians were asked to grade only unequivocally abnormal neuropathic signs (taking into account variables of age, sex, physical fitness, and physical characteristics), the intra-and inter-test variability was significantly lower [32] . These studies suggest that in clinical trials, NIS should be used only by expert examiners who have preliminary consensus training and surveillance throughout the study.
In controlled clinical trials, using qualified and trained neurologists as examiners, NIS has been used to assess disease progression and response to treatment in a number of polyneuropathies [22, [33] [34] [35] . In studies of patients with hATTR amyloidosis, NIS has been correlated to various measures of disease impairment, suggesting that the scale is of value for quantitative surveillance of severity of this disease. For example, in the first 100 patients of the phase III trial of the antisense oligonucleotide inotersen in patients with hATTR amyloidosis and polyneuropathy, total NIS was significantly correlated with functional health and disability scores including PND score, Dyck/Rankin score, and Inflammatory Neuropathy Cause and Treatment from Neuropathy Symptoms and Change. Furthermore, in an international natural history study of 283 patients with hATTR amyloidosis and polyneuropathy, NIS was positively associated with FAP staging and PND score [5] . Patients in this study had an estimated NIS increase of 14.3 points per year, suggesting more rapid disease progression than patients with diabetic polyneuropathy for whom the expected increase in NIS is 0.5 points per year [5, 24] .
NIS was used as a secondary endpoint in a controlled clinical study assessing the effect of diflunisal in patients with hATTR amyloidosis and polyneuropathy, and was able to detect a significant difference (p < 0.01) between treatment and placebo groups at 1 and 2 years (at 2 years, NIS scores increased by 22.8 points in the placebo group compared with 6.7 points in the diflunisal group) [20] . It was also the primary endpoint in a 3-year observational study of tafamidis treatment in 61 patients with hATTR amyloidosis and polyneuropathy, with patients having a mean increase of 15.6 points after 18 months of
A C C E P T E D M A N U S C R I P T 
NIS-LL
The NIS-LL is a subset of the NIS using measurements that quantify weakness, reflexes, and sensation in the lower limbs only, and has been primarily utilized in evaluation of length- 
Limitations of NIS and NIS-LL in hATTR amyloidosis
While NIS and NIS-LL have been used successfully in clinical trials of patients with hATTR amyloidosis, there is some variability inherently associated with the use of examiner-based
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The NIS+7 scale uses the same weakness, reflexes, and sensation measures as the NIS, combined with seven additional assessments that were included to better characterize and quantitate neuropathic impairment [30] . Five of these additional assessments are nerve conduction studies (NCS), focused on 3 nerves in the lower limbs: tibial nerve distal motor latency; peroneal nerve compound muscle action potential amplitude, distal motor latency and conduction velocity; and sural sensory nerve action potential amplitude [20, 25] . These NCS data measurements should be acquired using a uniform protocol and reviewed at a central center to ensure reproducibility [43] . The additional two components of the NIS+7 are vibration detection threshold (VDT), a sensory measure taken at the great toe, and heart rate response to deep breathing (HRdb), which serves as a measure of autonomic dysfunction.
Both are highly standardized and referenced tests [25, 44, 45] .
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The NIS+7 was developed and validated as an endpoint for clinical trials in diabetic sensorimotor polyneuropathy, which typically features milder neuropathic impairment than hATTR amyloidosis [30, 46] . However, NIS+7 was the primary endpoint in a controlled clinical study assessing the effect of diflunisal in patients with hATTR amyloidosis and polyneuropathy, and was able to detect a significant difference between treatment and placebo groups at 1 and 2 years (at 2 years, NIS+7 scores increased by 26.3 in the placebo group, and by 8.7 points in the diflunisal group) [20] .
One potential concern of adding neurophysiologic tests (such as NCS studies) to the measures of clinical signs already included in NIS (such as muscle weakness), is an overlap between clinical measurement of weakness of a muscle group and a neurophysiological measurement of a component of the same muscle group. However, including both testing types allows for the capture of a broad range of polyneuropathy dysfunction and provides the benefit of having both the more objective neurophysiologic tests and direct assessments of patient symptoms provided by the clinical signs testing. The neurophysiological tests can also be used as an independent confirmation of the clinical signs measurements.
Limitations of NIS+7
To test the suitability of the scale for patients with hATTR amyloidosis, a retrospective analysis of 97 patients was performed [25] . While NIS+7 adequately assessed weakness and muscle stretch reflexes, ceiling effects (patients at the maximal or minimal score available for their evaluation) were detected for sensation loss, nerve conduction abnormalities, and autonomic dysfunction. For example, the tests performed could not differentiate between a patient who had a loss of sensation only at the toes and a patient with loss of sensation from the knee downward. Large-fiber sensory dysfunction is also emphasized over small sensory fiber dysfunction, and sensation loss is underemphasized as NIS+7 is weighted toward weakness (71% of total score). Assessment of the five NCS suggested they were not ideally suited for studying hATTR amyloidosis as attributes were ACCEPTED MANUSCRIPT
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often unevaluable (for example, because amplitudes were zero). Finally, autonomic dysfunction was not adequately assessed by only using HRdb [25] .
mNIS+7 Alnylam and mNIS+7 Ionis
Incorporating the recommended changes to NIS+7, two recently completed phase III trials in hATTR amyloidosis with polyneuropathy have used modified versions of the NIS+7 as their primary endpoints. The APOLLO trial assessing the RNAi therapeutic patisiran used the mNIS+7Alnylam, whereas the NEURO-TTR trial assessing inotersen used a slightly different version termed the mNIS+7Ionis [26, 27] . These scales were designed to assess a broad range of abnormality, ranging from mild to severe, and are the first to be developed specifically for detecting polyneuropathy progression in clinical trials of patients with hATTR amyloidosis and polyneuropathy.
The mNIS+7Alnylam and mNIS+7Ionis scales both employ the same weakness and reflex assessments and scoring as the NIS, and include NCS measures that are revised from the NIS+7. Both tools discard VDT in sensation assessment, and instead include smart somatotopic quantitative sensation testing (S ST QST) [26, 27] . However, the mNIS+7Alnylam uses only S ST QST for sensory loss, whereas the mNIS+7Ionis also retains the NIS sensation measure (Table 2) . Finally, the mNIS+7Alnylam uses an alternative measure of autonomic dysfunction (postural hypotension), whilst the mNIS+7Ionis maintains HRdb ( Table   2 ). The differing components of the NIS+7, mNIS+7Alnylam, and mNIS+7Ionis are shown ( Fig. 2) and described in more detail below [26, 27] . 
Changes from NIS+7: sensation
Changes from NIS+7: NCS
In NIS+7 NCS, conduction velocity and distal latency measurements were often unmeasurable in patients with hATTR amyloidosis and acted as less direct measurements of muscle weakness or sensory loss [25] . Replacement of these with upper and lower limb amplitudes of motor and sensory nerve conductions (i.e. action potential amplitudes) in
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Changes from NIS+7: autonomic dysfunction
Autonomic dysfunction is measured and scored in the mNIS+7Ionis using HRdb. However, this assessment is not always measurable in patients with hATTR amyloidosis (e.g. due to cardiac arrhythmia or electronic pacing) [25, 27, 50]. To account for this, the measurement of postural hypotension was instead included in the mNIS+7Alnylam. The drawback of postural hypotension is that it is treatable with medical interventions (such as fludrocortisone) and this should be taken into account when it is assessed [26] . To ensure standardization, both endpoints were scored in the same manner as NCS in their relevant mNIS+7 scales.
Assessment of the mNIS+7 Alnylam and mNIS+7 Ionis in hATTR amyloidosis
Test/re-test reproducibility of the mNIS+7Ionis was assessed in the first 100 patients of the 
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methodology and ensure that scoring was as consistent and accurate as possible for both the APOLLO and NEURO-TTR trials [26, 27] . In terms of the mNIS+7 scales' linearity, the mNIS+7Alnylam was able to detect differences between treatment and placebo groups across different ranges of baseline polyneuropathy severity in the APOLLO study [51] . However, the impact of a specific change in mNIS+7 score in a patient with minimal polyneuropathy may not be the same as an equal change in score in a patient with severe polyneuropathy.
Comparability therefore depends on matching placebo versus treatment groups by the level of severity. As a result, the mNIS+7Alnylam and mNIS+7Ionis scales, the first designed specifically to assess impairment in hATTR amyloidosis clinical trials, were created and have been used as the primary endpoint in two recent phase III trials (Table 2) . In both trials, the mNIS+7 scales were able to detect improvements in polyneuropathy symptoms for treatment compared with A potential drawback of a composite scale such as mNIS+7 is assigning a degree of clinical meaning to a specific change in overall score. The variation in symptoms and disease severity also presents a challenge to relating an improvement in score to the benefits in a particular patient. However, it should be noted that for specific domains, for example muscle groups, the meaning of a 1-point change does reflect a known difference in muscle weakness or reflexes ( Table 2) . These demands are necessary if neuropathy impairment is to be assessed accurately, and data generated by differing investigators/centers are to be comparable.
Summary
The various neuropathic impairments and variable progression have presented challenges to developing a comprehensive measure for assessing polyneuropathy in hATTR amyloidosis.
While the initial use of disability assessments to categorize the disease in stages proved useful, more detailed measures were needed to track progression and compare treatment arms in controlled clinical trials. The NIS was therefore adopted from other neuropathies and has provided the basis for the primary endpoints of all major placebo-controlled trials in patients with hATTR amyloidosis and polyneuropathy. Testing of the NIS scores specifically in this disease has driven their evolution, with the mNIS+7 scales used as the primary endpoint in the most recent phase III trials designed to reflect the unique nature of polyneuropathy in hATTR amyloidosis. 
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